Neumora Therapeutics Plummets After Drug Trial Failure
Neumora Therapeutics shares hit rock bottom after its depression drug failed in a Phase 3 trial. Discover the impact on the company's stock and future prospects.
Topic
depression drug
A collection of 5 issues
Neumora Shares Dive as Depression Drug Fails Phase 3 Trial
Neumora Therapeutics shares nosedived after its promising depression drug failed in a crucial Phase 3 trial, impacting investor confidence. Learn more about the implications.
Neumora Therapeutics Shares Plummet 80% After Drug Trial Failure
Neumora Therapeutics stock plummets 80% to $2.05 after pivotal Phase 3 trial of their depression drug fails, impacting investor confidence.
Neumora's Stock Plummets After Depression Drug Trial Fails
Neumora Therapeutics Inc.'s shares drop after their depression drug's final-stage trial failure. Discover what this means for investors and the company's future.
Neumora's Depression Drug Trial Fails, Shares Plunge 82%
Neumora Therapeutics' depression drug falls short in final-stage trial, leading to an 82% pre-market share drop. Discover the impact on Neumora's future prospects.